Skip Navigation

Biocoat, Inc. names Robert Hergenrother senior director of research and development

Biocoat, Inc. announced today that Robert Hergenrother, Ph.D., has joined the company as senior director, research and development. Based in Horsham, PA, Biocoat develops and licenses biomaterial coatings for medical devices that are custom engineered to meet specific clinical design parameters. In this new position, Hergenrother will oversee research and development and new product innovation for Biocoat.

“Bob is an outstanding addition to our team and will play a key role in our continued growth. His broad experience in research and development, as well as new product innovation, will ensure we continue to make the best possible use of resources, while his drive to innovate and his management skills will enhance our ability to capitalize on new market opportunities,” said Jim Moran, president and CEO, Biocoat.

Prior to joining Biocoat, Hergenrother was director of medical technology development at Southern Research and a professor of biomedical engineering at the University of Alabama at Birmingham (UAB). He led a partnership between the two organizations to identify and encourage UAB inventors with medical device ideas, and to commercialize new technologies that emerged at the school. Hergenrother has led the launch of more than 15 new products in his career. He holds 22 U.S. patents covering a range of technologies in the medical device and biomaterial space, and has 29 publications in scientific journals.

“Biocoat will play an increasingly important role in health care, as the industry remains focused on improving patient outcomes and as the introduction of medical devices continues to soar,” said Hergenrother. “I look forward to working with this innovative team to develop and launch new solutions that improve the performance of medical devices and procedures for clinicians and patients alike.”

Earlier in his career, Hergenrother held multiple positions at Surmodics, Inc., serving most recently as senior director of research and development, and at Target Therapeutics (now Stryker Neurovascular), where he developed endovascular medical devices to treat diseases of the brain. He earned a bachelor of science degree in chemical engineering from the University of Notre Dame and a Ph.D. in chemical engineering from the University of Wisconsin-Madison.

More Alumni Notes

Join us for Recent-Grad Weekend on campus June 7–8 for two days packed with all-inclusive summertime fun. Register now before it sells out!